Covalon TechnologiesCVALF -1.79%83 Cyclically Adjusted PS Ratio is 1.74 as of Jul. 09, 2026, which is 23% below its 10-year median of 2.25. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.53 (Fairly Valued). The stock has 2 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Covalon Technologies ranks better than 59.27% on this metric.
The historical rank and industry rank for Covalon Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:
CVALF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.86 Med: 2.25 Max: 12.75
Current: 1.72
During the past years, Covalon Technologies's highest Cyclically Adjusted PS Ratio was 12.75. The lowest was 0.86. And the median was 2.25.
CVALF's Cyclically Adjusted PS Ratio is ranked better than 59.27% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 2.3
vs CVALF: 1.72
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Covalon Technologies's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.229. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.87 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Covalon Technologies (OTCPK:CVALF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Covalon Technologies Cyclically Adjusted PS Ratio Related Terms
Covalon Technologies Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies Cyclically Adjusted PS Ratio Chart
CVALF vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Cyclically Adjusted PS Ratio falls into.
Covalon Technologies Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.74 mean?
Covalon Technologies (CVALF) has a Cyclically Adjusted PS Ratio of 1.74 as of Jul. 09, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Covalon Technologies and its competitors. This is 23% below median its historical median of 2.25. Over the past decade, Covalon Technologies' Cyclically Adjusted PS Ratio has ranged from 0.86 to 12.75. According to the industry distribution chart, Covalon Technologies ranks #213 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is Covalon Technologies' Cyclically Adjusted PS Ratio too high?
Covalon Technologies' current Cyclically Adjusted PS Ratio of 1.74 is 23% below median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 12.75. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.30. Covalon Technologies' value of 1.74 is 24.3% below this industry median. Based on the distribution chart, Covalon Technologies ranks #213 out of 523 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Cyclically Adjusted PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #213 out of 523 companies for Cyclically Adjusted PS Ratio. This puts Covalon Technologies in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.30. Covalon Technologies' value of 1.74 is 24.3% below this benchmark. Historically, Covalon Technologies' own Cyclically Adjusted PS Ratio has ranged from 0.86 to 12.75 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 2.30, Covalon Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.30, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Cyclically Adjusted PS Ratio of 1.74 is 24.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Cyclically Adjusted PS Ratio is 1.74, which is 23% below median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.53, compared to a current price of $1.51 — trading 1.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.74, which is 23% below median its 10-year median of 2.25 and 24.3% below the Medical Devices & Instruments industry median of 2.30. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Cyclically Adjusted PS Ratio is 1.74 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.51 is trading 1.3% below its estimated GF Value™ of $1.53.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Cyclically Adjusted PS Ratio: 1.74 (23% below median its 10-year median of 2.25)
GF Value™: $1.53 vs. price of $1.51 (1.3% below fair value)
Industry Position: 24.3% below the Medical Devices & Instruments median (#213 of 523)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
